CFDE Data Portal | Search LOC105370109

	Label	Description
	LOC105370109 Gene (Entity type)	ENSG00000262198 - uncharacterized LOC105370109
	GSE80098 GSE80366 progesterone 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 0 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE190178 MEK CDK8 inhibition 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 5 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE139016 disulfiram 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE156761 dopamine neuron 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130437 palbociclib 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

LOC105370109

ENSG00000262198 - uncharacterized LOC105370109

GSE80098 GSE80366 progesterone 0 v 8 human up

A Gene Set from LINCS

GSE115542 digoxin 2 v 0 human up

A Gene Set from LINCS

GSE146982 metformin 0 v 6 human dn

A Gene Set from LINCS

GSE216043 cisplatin 11 v 1 human dn

A Gene Set from LINCS

GSE190178 MEK CDK8 inhibition 1 v 4 human up

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 5 v 0 human dn

A Gene Set from LINCS

GSE139016 disulfiram 3 v 1 human dn

A Gene Set from LINCS

GSE156761 dopamine neuron 0 v 3 human dn

A Gene Set from LINCS

GSE130437 palbociclib 2 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.